Radiopharm Theranostics doses first patient in second cohort of RV-01 Phase 1/2a trial in B7-H3 solid tumorsPUBT·Aug 26 at 11:03 AMRADX-4.85%
Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC reviewPUBT·Aug 20 at 11:03 AMRADX-4.85%
Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agentPUBT·Aug 17 at 12:03 PMRADX-4.85%
Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialPUBT·Aug 17 at 11:31 AMRADX-4.85%
Radiopharm Theranostics Lifts Cap on Securities Purchase Plan to AUD10 MillionTip Ranks·Aug 5 at 04:02 AMRADX-4.85%
Radiopharm Theranostics plans Phase 3 registrational trial of imaging agent RAD101 in Q4 2026PUBT·Jul 31 at 11:01 AMRADX-4.85%SHL
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Jul 29 at 12:05 PMNEO-0.29%AMIX-5.06%
U.S. stock market midday update: Radiopharm Theranostics down 14.48%, clinical benefits unable to mask losses and valuation risksPrice Alert·Jul 28 at 04:48 PMRADX-4.85%
Radiopharm Theranostics Secures Multimillion-Dollar Financings to Advance Oncology Radiopharmaceutical PipelineTip Ranks·Jul 28 at 04:27 PMRADX-4.85%
Radiopharm Theranostics announces extraordinary general meeting for shareholder approvalsPUBT·Jul 28 at 04:00 PMRADX-4.85%
U.S. stock night market opening fluctuations: Radiopharm Theranostics fell 7.65% in the night market; Cadence Design rose 3.50% in the night marketPrice Alert·Jul 28 at 12:12 AMRADX-4.85%CDNS-2.03%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Jul 27 at 09:06 PMRDHL-14.83%OPK+11.18%
